Table A2.

Uncontrolled studies

References	Study design	Sample size	Study duration	Type of the drug and route of administration	Measures	Main findings	Adverse events
		Age
		Disease duration
Frankel et al. [164]	Case series	N = 5	NR	1. Smoked cannabis (1 g with 2.9% THC)	Webster scale	No improvement of tremor	Drowsiness or mild euphoria
		Age: NR
		Dd: NR
				2. Diazepam 5 mg orally			Mild unsteadiness occurred after diazepam
				3. l-DOPA/Carbidopa 250 mg/25 mg orally (Sinemet 275)
				4. Apomorphine 1.5 mg subcutaneously
Venderová et al. [162]	Open-label pilot	N = 85 of 339	—	84 patients with ½ teaspoon cannabis orally; 1 patient by inhalation	Anonymous questionnaire sent by mail	31% reported improvement of rest tremor, 45% of bradykinesia and 14% of LID	Unspecified
		Age: 65.7 yearsDd: 8.5 yeasr
				52.9% daily
Zuardi et al. [165]	Open-label pilot	N = 6	4 weeks	1st week:150 mg/day	1.BPRS	Improvement of psychiatric plus and minus symptoms, mild improvement	None
				2nd week:250 mg/day	2. PPQ
		Age: 58.8 ± 14.9 years		3rd week: 325 mg/day	3. UPDRS total
				4th week: 400 mg/day	4. CGI-I
		Dd: 10.6 ± 3.7 years		CBD dissolved in corn oil	5. MMSE
				Placebo group: corn oil capsules	6. FAB
Chagas et al. [ 60 ]	Case series	4 patients with RBD	6 weeks	75 or 300 mg/day CBD	REM Sleep behavior disorder questionnaire	Significant improvements in sleep symptoms; Well tolerated	NR
Finseth et al. [166]	Patient survey	N = 9	—	Past or current use of Cannabis	Self-administered questionnaire via e-mail	Benefits in mood (56%), sleep (56%), motor symptoms (22%), and quality of life (22%)	None
		Age: 49–75 years
		Dd: 2–11 years
Lotan et al. [167]	Case series	N = 22	Smoked cannabis for at least 2 months	Smoked cannabis, 0.5 g (with 2.9% THC)	UPDRS VAS Pain intensity scale Short-Form McGill Pain Questionnaire Medical Cannabis Survey National Drug and Alcohol Research Center Questionnaire	Improvement of tremor and bradykinesia and some non-motor symptoms	Short-term: hypoglycemia, dizzinessLong-term: somnolence, drowsiness, palpitations, bad taste
		Age: 65 ± 10.2 yearsDd: 7.3 ± 4.8 years
Shohet et al. [168]	Open-label, observational	N = 20	Cannabis use for at least 10 weeks (median 14 weeks)	Vaporizer or smoking Cannabis (1 g), anticholinergic agents, dopamine agonists, amantadine, and rasagiline	1. UPDRS	Improvement in mean motor and pain scores in 18PD patients	NR
					2. PRI
					3. Short-form McGill Pain Questionnaire 4.VAS
		Age: 62.4 ± 9 years
		Dd: 6.8 ± 3.5 years
		Control: 12 Age: 70 ± 7.2 years
		Dd: 6 ± 2.6 years
Yust-Katz et al. [169]	Open-label	N = 114	—	Medical cannabis (MC), anti- Parkinson medication, pain killers (paracetamol, NSAID), opiates (Tramadol, Oxycodone)	1. UPDRS	MC significantly alleviated pain	NR
		Age: 68 ± 9.9 years			2. McGill test	No significant difference in different pain medications (pain killers vs opiates vs MC)
		Dd: 6 ± 6 years			3. Structured questionnaire for pain typ
Balash et al. [170]	Retrospective observational telephone survey	N = 47	Patients treated for at least 3 months with MC	Most means of cannabis administration was Smoking flowers and leaves or oil ingestion daily dose 0.9 ± 0.5 g	Structured questionnaire	Improvement in pain, sleep, mood, and significant reduction of falls were reported by a significant percentage of patients.	Cough (34.9%), anxiety, confusion, and hallucinations
		Age: 64.2 ± 10.8 years
		Dd: 10.8 ± 8.3 years
Kindred et al. [171]	Open anonymous web-based survey	N = 453	—	Most reported routes of administration: smoking cannabis edible	Self-reported scales: GNDS, NHP, ABC, FSS, IPAQ	Improvement on mood, memory, fatigue, and obesity status, and reduction of prescribed medication	NR
		Age: 61.1 ± 9.5 years
				Smoked + edibles

Rows in bold emphasis indicate studies using CBD.